Microprofit Biotech, as a national high-tech enterprise, consistently pays much attention to manufacture, R&D, marketing and sales of in vitro diagnosis (IVD) products. The official brand of Microprofit Biotech, fluorecare, has dedicated to entire products of point-of-care (POC) tests based on immunofluorescence quantitative assay platform, which are applied to monitor and prognosis of human diseases with comprehensive parameters, including tumor markers, hormone markers, cardiac markers, infection markers and diabetes markers.
Microprofit fluorecare Immunofluorescence Quantitative Platform uses immunochromatographic technology, aiming for the diagnosis of common human diseases. Based on specific antigen-antibody reaction, the triggered fluorescence of the fluorochrome-labeled complexes is collected and automatically calculated. For certain analyte, including serum, plasma, urine or other sample, fluorecare is able to measure the concentration of various biological markers including tumor markers, hormone markers, infection markers, cardiac markers and diabetes markers with excellent accuracy and easy operation.
In Chinese domestic market, Microprofit Biotech provides high-value products and services for the diagnosis of reproductive system disorders. We originally researched and developed the genital tract infection pathogen detection kits (immunofluorescence assay). They have obtained the third accreditation from the China Food and Drug Administration (CFDA). Our detection kits are able to quickly test the infection of GardnerellaVaginalis, Candida Albicans, Trichomonas Vaginalis, Neisseria Gonorrhoeae and Chlamydia Trachomatis. The tests can be accurately completed in a short time without tedious operation. Our kits have been widely used in the domestic top level hospitals especially in which specialized for women and child. Our genital tract infection pathogen detection kits have received unanimous recognition and praise from obstetrics and gynecology
Microprofit fluorecare Immunofluorescence Quantitative Platform uses immunochromatographic technology, aiming for the diagnosis of common human diseases. Based on specific antigen-antibody reaction, the triggered fluorescence of the fluorochrome-labeled complexes is collected and automatically calculated. For certain analyte, including serum, plasma, urine or other sample, fluorecare is able to measure the concentration of various biological markers including tumor markers, hormone markers, infection markers, cardiac markers and diabetes markers with excellent accuracy and easy operation.
In Chinese domestic market, Microprofit Biotech provides high-value products and services for the diagnosis of reproductive system disorders. We originally researched and developed the genital tract infection pathogen detection kits (immunofluorescence assay). They have obtained the third accreditation from the China Food and Drug Administration (CFDA). Our detection kits are able to quickly test the infection of GardnerellaVaginalis, Candida Albicans, Trichomonas Vaginalis, Neisseria Gonorrhoeae and Chlamydia Trachomatis. The tests can be accurately completed in a short time without tedious operation. Our kits have been widely used in the domestic top level hospitals especially in which specialized for women and child. Our genital tract infection pathogen detection kits have received unanimous recognition and praise from obstetrics and gynecology
Congratulations! A CE certification has obtained for fully at-home test of the SARS-CoV-2
As a national high-tech enterprise, MicroprofitBiotech consistently pays much attention to manufacture, R&D, marketing andsales of in vitro diagnosis (IVD) products. The official brand of MicroprofitBiotech, fluorecare, has dedicated to entire products of point-of-care (POC)test using immunofluorescence quantitative assay platform, which are applied tomonitor and prognosis of human diseases with comprehensive parameters,including tumor markers, hormone markers, cardiac markers, infection markersand diabetes markers.
A performance evaluation report from Etilab SA, Switzerland
Antigen Rapid Test (Colloidal Gold) using a lateral flow immunofluorescent sandwich assay to detects the novel coronavirus in human nasopharyngeal(NP) or nasal swabs sample. COVID-19 antigen can detect the presence of viral protein. It can identify acute or early infection. Suitable for large-scale screening of the general population and epidemiological investigations in low-endemic areas.
A performance evaluation report from Etilab SA, Switzerland
As a national high-tech enterprise, MicroprofitBiotech consistently pays much attention to manufacture, R&D, marketing andsales of in vitro diagnosis (IVD) products. The official brand of MicroprofitBiotech, fluorecare, has dedicated to entire products of point-of-care (POC)test using immunofluorescence quantitative assay platform, which are applied tomonitor and prognosis of human diseases with comprehensive parameters,including tumor markers, hormone markers, cardiac markers, infection markersand diabetes markers.